Location History:
- Mittelbiberach, DE (2015)
- Essen, DE (2016)
Company Filing History:
Years Active: 2015-2016
Title: Kathrin Riemann: Innovator in Cancer Genetics
Introduction
Kathrin Riemann is a prominent inventor based in Essen, Germany. She has made significant contributions to the field of cancer genetics, particularly through her innovative research and patented inventions. With a total of 2 patents, her work focuses on genetic modifications that can aid in predicting cancer risks and treatment responses.
Latest Patents
Riemann's latest patents include groundbreaking inventions related to the CHK2 gene and the CHK1 gene. The first patent, titled "CHK2 polymorphism as a cancer marker," involves the use of gene modifications in the human gene CHK2, which encodes checkpoint kinase 2. This invention aims to predict the risk and progression of cancer diseases, as well as the response to various therapeutic measures. It also addresses the detection and validation of individual gene variants that can be utilized for these purposes.
The second patent, "Use of genetic modifications in human gene CHK1 which codes for checkpoint kinase 1," describes an in vitro method for predicting disease risks and treatment success. This method focuses on identifying genetic modifications in the promoter region of the CHK1 gene, which can be detected individually or in combinations using established techniques.
Career Highlights
Kathrin Riemann has worked at notable institutions, including the University of Duisburg-Essen. Her research has significantly advanced the understanding of genetic factors in cancer, contributing to the development of predictive tools for disease management.
Collaborations
Riemann has collaborated with Winfried Siffert, enhancing her research efforts and expanding the impact of her work in the field of cancer genetics.
Conclusion
Kathrin Riemann's innovative contributions to cancer genetics through her patents and research highlight her role as a leading inventor in this critical area of study. Her work continues to pave the way for advancements in cancer prediction and treatment.